New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours

akronüüm: PREDECT
algus: 2011-02-01
lõpp: 2016-01-31
 
programm: FP7 - Euroopa Liidu 7. raamprogramm
alaprogramm: SP1-JTI - Joint Technology Initiatives (Annex IV-SP1)
instrument: JTI-CP-IMI
projektikonkurss: IMI-JU-2009
projekti number: 115188
kestus kuudes: 60
partnerite arv: 21
 
lühikokkuvõte: Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel therapeutic targets. Known targets, in canonical pathways, will be interrogated for induction of phenotypic, proteomic and transcriptomic changes using inhibitors. A strategy of seeking a ‘dynamic reciprocity’ of concordance between the steady and perturbed states of in vitro complex cultures, tissue slices and in vivo tumour models will be pursued by systems biology analyses. Comparison with historic gene expression and genomic data from relevant clinical materials should permit the emergence of faithful models for target validation and beyond. PREDECT is coordinated by Servier and AstraZeneca, and the managing
partneri jrk nr ja roll partneri nimi riik kontaktisik koduleht
1 koordinaator INSTITUT DE RECHERCHES SERVIER FR Esther Schenker http://www.seivier.com
2 partner University of Helsinki FI Emmy VERSCHUREN http://www.helsinki.fi/university/
3 partner Teknologian Tutkimuskeskus VTT FI Matthias Nees http://www.vtt.fi
5 partner ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH Cathrin BRISKEN http://www.epfl.ch/index.en.html
6 partner WEIZMANN INSTITUTE OF SCIENCE IL Varda ROTTER http://www.weizmann.ac.il/
7 partner Instituto de Biologia Experimental e Tecnológica PT Catarina BRITO http://www.ibet.pt/
8 partner Stichting Katholieke Universiteit Radboud university medical center NL Wim van den Berg http://www.radboudumc.nl
9 partner Erasmus Universitair Medisch Centrum Rotterdam NL Guido JENSTER http://www.erasmusmc.nl
10 partner Tartu Ülikool EE Jaak VILO http://www.ut.ee
11 partner Oncotest GmbH DE Heinz-Herbert Fiebig http://www.oncotest.de/
12 partner Biomedicum Genomics Ltd FI Outi Maria Monni http://www.biomedicumgenomics.fi
13 partner AstraZeneca AB SE Keith Tan http://www.astrazeneca.com
14 partner Bayer Pharma AG DE Matthias Gottwald http://www.bayerscheringpharma.de
15 partner Orion Pharma FI Pekka Kallio http://www
17 partner F. HOFFMANN-LA ROCHE AG CH Everson Nogoceke http://www.roche.com
18 partner Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. IT Loredana Vesci http://www
19 partner Boehringer Ingelheim International GmbH DE Michael Mark http://www.boehringer-ingelheim.com
20 partner Robert Bosch Gesellschaft fuer medizinische Forschung mbH DE Heiko van der Kuip http://www.ikp-stuttgart.de
21 partner Janssen Pharmaceutica NV BE Ralph Graeser http://www.janssenpharmaceutica.be
22 partner Cardiff University UK Sam Salek http://www.cardiff.ac.uk